Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHamish WalkerPAPhilippe ArmandRMReid W. Merryman

Discussion

Loading...

Member takes

Overview

Phase II trial shows increased regulatory T cells and Naïve T cells, suggesting rituximab improves immune response in follicular lymphoma.

Key Points

  • This research examines immune cell dynamics following combination therapy with rituximab and epcoritamab for follicular lymphoma.
  • Phase II multicenter trial assessing treatment in previously untreated patients with high-tumor burden FL.
  • Patients received debulking treatment with rituximab followed by epcoritamab in a time-limited protocol.
  • Conducted spectral flow cytometry to analyze T-cell and B-cell populations across multiple timepoints.
  • Best complete metabolic response (CMR) rate of 91% noted post-treatment.
  • Notable increase in naive T cells for patients experiencing lower grades of cytokine release syndrome.
  • Significant depletion of CD19+ CD20+ B cells observed post-rituximab treatment.

Cite This Study

Walker et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d260https://doi.org/10.1182/blood-2025-1790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  2. 2primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  3. 3Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress2025
  4. 4Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 2 citations
  5. 5Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study2025